US services PMI recently hit a multi month high, highlighting how services activity is still carrying much of the growth story into late 2026. That keeps attention on companies that can grow earnings even as costs and interest rates stay in focus. The healthy high growth potential screener filters for stocks that meet this test. This article highlights three of the strongest candidates from that list.

The stocks covered below are just a small sample of this idea. The full screen surfaced 1,538 more companies with equally compelling growth and financial strength stories that are not detailed here. To see the wider opportunity set, head straight into the Healthy high growth potential screener and use it to identify, filter and analyze the highest conviction plays for your watchlist.

Amylyx Pharmaceuticals (AMLX)

Amylyx Pharmaceuticals is a US based clinical stage biotech focused on treating neurodegenerative diseases and rare endocrine conditions, which aligns it closely with the Healthy high growth potential theme through pipeline assets like AMX0114 and AMX0035. The company currently does not report product revenue, so the story today is about future potential rather than existing sales. Amylyx Pharmaceuticals has a market cap of about US$4.3b.

Investors looking at Amylyx Pharmaceuticals are really looking at whether avexitide and the broader GLP 1 and neurodegeneration pipeline can turn a research story into a commercial growth story. Positive LUCIDITY Phase 3 data in post bariatric hypoglycemia and plans for a 2027 launch, backed by fresh equity funding, provide more visibility on how that first revenue leg might form. At the same time, losses remain significant, the company is relying on external capital and dilution has increased, so execution on trial milestones and payer uptake needs to justify the current expectations. The key question is whether AMX0114, AMX0035 and avexitide together can support the earnings trajectory analysts are modelling, or whether clinical and funding risks will slow that path.

Amylyx Pharmaceuticals has an ambitious earnings story built on future launches rather than current sales, and that gap between promise and proof makes the next phase critical for investors weighing risk against reward. Get the full context in the analyst forecasts for Amylyx Pharmaceuticals

Build your own high growth shortlist

Amylyx Pharmaceuticals and the two other stocks in this article all came from a single Simply Wall St screen, which you can easily recreate and refine. Use our customisable Screener to blend filters like future growth, financial health and risk, or tap into our curated Investing Ideas for ready made shortlists built around different themes.

Oracle (ORCL)

Oracle is a global enterprise software and cloud company best known for its databases and the Oracle Cloud SaaS suite, including Fusion Cloud ERP, HCM, SCM and NetSuite. This is the clearest link to the Healthy high growth potential theme as analysts focus on subscription and support revenue migrating into the cloud. The business is still diversified, with around US$58.5b of revenue from cloud and software, US$5.7b from services and US$3.1b from hardware. Oracle is a large cap stock with a market value of roughly US$421.9b.

Investors watching Oracle are really watching whether its cloud SaaS and AI infrastructure story can justify the strong earnings growth forecasts that put it into this screener. Massive AI and cloud contracts, a very large reported backlog and deep ties across enterprise, government and healthcare hint at years of subscription revenue potential. At the same time, high debt levels and heavy data center spending keep execution risk firmly on the table. If Oracle converts that contracted demand into sustainable cash flows without stretching the balance sheet too far, the combination of growth, scale and a multi-cloud position could be hard to ignore.

Oracle’s cloud and AI story is accelerating, but the real test is how that affects the balance sheet and cash generation. Get the full picture in the Oracle financial health report

Iovance Biotherapeutics (IOVA)

Iovance Biotherapeutics is a US based commercial stage biotech focused on autologous tumor infiltrating lymphocyte cell therapies, with Amtagvi for advanced melanoma and late stage candidates like lifileucel anchoring its fit with the Healthy high growth potential theme. The company currently generates about US$325 million from its single segment of innovating, developing and commercializing these TIL based therapies and related products. Iovance Biotherapeutics has a market cap of roughly US$3.8b.

Iovance Biotherapeutics is drawing fresh interest because Amtagvi is already on the market, revenue is forecast to grow quickly and earnings are expected to move from losses to profitability within the next 3 years, all while the TIL platform is being tested in high impact cancers like lung and cervical. Recent record quarterly revenue, improving gross margins and a rapidly expanding network of treatment centers suggest the commercial engine is gaining traction, yet the stock still trades at a steep discount to some fair value estimates while relying on higher risk external funding and accepting shareholder dilution to keep trials and manufacturing moving. For investors who can handle volatility and execution risk, the combination of a first in class TIL therapy, a broad pipeline and rising analyst interest may be too important to ignore.

Iovance Biotherapeutics already has Amtagvi on the market and a broad TIL pipeline that many investors may be overlooking. Get the more complete growth and risk story in the analysis report for Iovance Biotherapeutics

Seeking Fresh Alternatives Before They Fly

Fresh stock ideas can move from under the radar to fully priced faster than many investors expect. Scan for breakouts before the crowd catches up and consider acting earlier in your process.

• Target reliable income streams while rate expectations keep shifting by checking stocks in the 12 dividend fortresses that currently combine higher yields with resilient business profiles.
• Look for early AI participants involved in the picks-and-shovels side of the trend by using the curated 55 AI infrastructure stocks to identify momentum before valuations potentially rise.
• Track companies that appear positioned for an electrification build out using the hand picked 39 power grid technology and infrastructure stocks to see which stocks may benefit if grid spending increases.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.